In August 2023, the patient began first-line systemic therapy for ER+/HER2-low advanced breast cancer, consisting of the CDK4/6 inhibitor dalpiciclib (125 mg orally once daily) combined with the aromatase inhibitor fulvestrant (500 mg intramuscularly every 4 weeks). This evidence concerns the gene ERBB2 and breast carcinoma.